Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,313 Shares of Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,313 shares of the stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total value of $537,313.54. Following the sale, the chief operating officer directly owned 2,165 shares of the company’s stock, valued at $269,715.70. The trade was a 66.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, September 16th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $152.24, for a total value of $654,936.48.
• On Wednesday, August 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The shares were sold at an average price of $152.21, for a total value of $654,807.42.

Palvella Therapeutics Price Performance

Palvella Therapeutics stock opened at $125.10 on Friday. Palvella Therapeutics, Inc. has a 12 month low of $68.96 and a 12 month high of $161.38. The business has a 50 day simple moving average of $142.46 and a 200-day simple moving average of $134.48. The stock has a market capitalization of $1.80 billion, a PE ratio of -25.90 and a beta of -0.27.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). As a group, equities research analysts anticipate that Palvella Therapeutics, Inc. will post -6.41 EPS for the current year.

Wall Street Analyst Weigh In

PVLA has been the topic of several analyst reports. William Blair began coverage on shares of Palvella Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Truist Financial set a $207.00 price target on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Raymond James Financial set a $226.00 price objective on shares of Palvella Therapeutics in a research report on Friday, October 16th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Palvella Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $209.79.

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC increased its holdings in Palvella Therapeutics by 907.7% in the third quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock valued at $54,000 after buying an additional 354 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in shares of Palvella Therapeutics during the 3rd quarter worth approximately $212,000. Arizona State Retirement System boosted its stake in shares of Palvella Therapeutics by 30.9% during the 2nd quarter. Arizona State Retirement System now owns 2,765 shares of the company’s stock worth $423,000 after acquiring an additional 652 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Palvella Therapeutics during the 2nd quarter worth approximately $35,000. Finally, Penn Capital Management Company LLC acquired a new stake in shares of Palvella Therapeutics in the 2nd quarter worth approximately $841,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.